Off-label use of medicines: consensus recommendations for evaluating appropriateness

被引:155
作者
Gazarian, Madlen [1 ]
Kelly, Maria
McPhee, John R.
Graudins, Linda V.
Ward, Robyn L.
Campbell, Terence J.
机构
[1] Univ New S Wales, Sydney, NSW, Australia
[2] Sydney Childrens Hosp, Randwick, NSW, Australia
[3] NSW Therapeut Advisory Grp, Sydney, NSW, Australia
[4] Univ Sydney, Ctr Values Eth & Law Med, Sydney, NSW 2006, Australia
[5] St Vincent Hosp, Sydney, NSW, Australia
关键词
D O I
10.5694/j.1326-5377.2006.tb00689.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Off-label prescribing is the prescription of a registered medicine for a use that is not included in the product information. The practice is common, with rates up to 40% in adults and up to 90% in paediatric patients. Off-label prescribing is not illegal and may sometimes be clinically appropriate, but is associated with a number of clinical, safety and ethical issues. To date, no explicit guidance has been available to help clinicians assess appropriateness in off-label prescribing. We describe the development of a guide for clinicians, policymakers and funders of health care in evaluating the appropriateness of medicines proposed for off-label use. Three broad categories of appropriate off-label use are identified: off-label use justified by high-quality evidence; use within the context of a formal research proposal; and exceptional use, justified by individual clinical circumstances. An appropriate process for informed consent is proposed for each category. If there is no high-quality evidence supporting off-label use, and the medicine is not suitable for exceptional or research indications, its use is generally not recommended. This will reduce inappropriate use, enhance patient safety by reducing exposure to unnecessary risk, and may stimulate more clinically relevant medicines research.
引用
收藏
页码:544 / 548
页数:5
相关论文
共 40 条
[1]   Legal considerations in off-label medication prescribing [J].
Blum, RS .
ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (15) :1777-1779
[2]   Off-label drug use in human immunodeficiency virus disease [J].
Brosgart, CL ;
Mitchell, T ;
Charlebois, E ;
Coleman, R ;
Mehalko, S ;
Young, J ;
Abrams, DI .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1996, 12 (01) :56-62
[3]   Dose discrepancies between the Physicians' Desk Reference and the medical literature, and their possible role in the high incidence of dose-related adverse drug events [J].
Cohen, JS .
ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (07) :957-964
[4]   Paediatric prescribing: using unlicensed drugs and medicines outside their licensed indications [J].
Collier, J .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 48 (01) :5-8
[5]   Survey of unlicensed and off label drug use in paediatric wards in European countries [J].
Conroy, S ;
Choonara, I ;
Impicciatore, P ;
Mohn, A ;
Arnell, H ;
Rane, AR ;
Knoeppel, C ;
Seyberth, H ;
Pandolfini, C ;
Raffaelli, MP ;
Rocchi, F ;
Bonati, M ;
't Jong, G ;
de Hoog, M ;
van den Anker, J .
BRITISH MEDICAL JOURNAL, 2000, 320 (7227) :79-82
[6]   Evidence-based medicine: useful tools for decision making [J].
Craig, JC ;
Irwig, LM ;
Stockler, MR .
MEDICAL JOURNAL OF AUSTRALIA, 2001, 174 (05) :248-253
[7]   Unlicensed and off-label uses of drugs in paediatrics: a review of the literature [J].
Cuzzolin, L ;
Zaccaron, A ;
Fanos, V .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2003, 17 (01) :125-131
[8]   Users' guides to the medical literature - XIV. How to decide on the applicability of clinical trial results to your patient [J].
Dans, AL ;
Dans, LF ;
Guyatt, GH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (07) :545-549
[9]  
Douglas-Hall P, 2001, PHARM J, V267, P890
[10]   Off-label prescribing to children: attitudes and experience of general practitioners [J].
Ekins-Daukes, S ;
Helms, PJ ;
Taylor, MW ;
McLay, JS .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (02) :145-149